What does this research mean for the field?

First-line treatment with zongertinib demonstrates sustained efficacy and predominantly low-grade adverse events in patients with advanced or metastatic HER2-mutant non-small-cell lung cancer. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

The aim is to evaluate the efficacy and safety of zongertinib in untreated patients with advanced HER2-mutant non-small-cell lung cancer (NSCLC).

April 18, 2026

First-Line Zongertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer

Key Points

The aim is to evaluate the efficacy and safety of zongertinib in untreated patients with advanced HER2-mutant non-small-cell lung cancer (NSCLC).
Clinical trial design focusing on previously untreated patients
Assessment of treatment-related adverse events
Evaluation of drug efficacy over time
Zongertinib shows sustained efficacy in advanced or metastatic HER2-mutant NSCLC
Adverse events related to treatment were mostly low-grade

Abstract

Zongertinib showed sustained efficacy in previously untreated patients with advanced or metastatic HER2-mutant NSCLC. Treatment-related adverse events were predominantly low-grade. (Funded by Boehringer Ingelheim; Beamion LUNG-1 ClinicalTrials.gov number, NCT04886804.).

First-Line Zongertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer

Key Points

Abstract

Cite This Study

Also Consider

Also Consider